FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.
FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands is now open and fully operational, the company announced on Dec. 8, 2021. The new facility provides life science manufacturing and, with the company’s other manufacturing locations in the United States and Japan, increases production capacity of cell culture media products. The Tilburg site acts as a hub for both European and global markets.
The Tilburg site is the third manufacturing facility in FUJIFILM Irvine Scientific’s roster and represents an important step in the company’s long-term plans to secure its production capacity to meet growing market demand. The facility’s location in central Europe makes it a source of local supply, increasing supply chain efficiency and enabling cost-savings in shipping.
The facility was built on sustainable initiatives following the parent company’s Fujifilm Sustainability Value Plan 2030. Strategies in use at the new facility include working towards a carbon dioxide-neutral status, using wind energy for production process, and using sustainable technologies. such as membrane bioreactors, for wastewater purification.
The Tilburg facility uses approximately 13,500 m2 of space and manufactures dry powder media, liquid media, buffers, and water for injection. The facility initially increases the company’s production capacity with approximately 320,000 kg/year of dry powder media and greater than 470,000 L/year of liquids. The company can also expand rapidly if the necessity arises.
“We worked steadily to achieve milestones for construction, validation, and commissioning of this manufacturing facility,” said Yutaka Yamaguchi, chairman and CEO, FUJIFILM Irvine Scientific, in a company press release. “Even with the global challenges faced in recent years, FUJIFILM Irvine Scientific was determined to provide customers in Europe with local service that strengthens the supply chain and increases manufacturing capacity. It is extremely rewarding to see this commitment realized.”
Source: FUJIFILM Irvine Scientific
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.